Charmacy Pharmaceutical Co., Ltd. (Stock Code: 2289) has released a notice regarding the extraordinary general meeting (EGM) scheduled for 12 December 2025 at 3:00 p.m. The event is set to take place in the conference room on the 2nd Floor of No. 33 Liyu Street, Dongchong Town, Nansha District, Guangzhou City, Guangdong Province, PRC.

Charmacy Pharmaceutical intends to review and, if deemed appropriate, approve multiple resolutions. These include a new framework loan agreement with Jiangyao Group Co., Ltd., authorizing relevant terms related to the agreement’s loan facility. A further resolution involves granting authorization to a member of the board to determine commercial terms, sign documents, and take steps to finalize transactions under the agreement. Additional items include the proposed appointment of Pan-China Certified Public Accountants LLP as the auditors for the fiscal year ending 31 December 2025 and the proposed amendments to the company’s articles of association, rules of procedures for general meetings, and rules of procedures for board meetings.

Shareholders seeking more information are advised to refer to the circular dated 24 November 2025 for complete details on the proposed resolutions and related instructions.